Innovent Biologics, Inc. (1801.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Innovent Biologics, Inc.
Address
168 Dongping Street
Suzhou, 215123
China
Phone
86 512 6956 6088
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5659
First IPO Date
October 31, 2018
Key Executives
| Name | Title | Pay | Year Born |
| De-Chao Yu | Co-Founder, Chairman & Chief Executive Officer | 49.49M | 1964 |
| Qian Zhang | Chief Commercial Officer, General Manager & Executive Director | 4.88M | 1987 |
| Hao Xi Ede | Executive Director & Fund Managing Partner | 8.08M | 1959 |
| Cong Ding | General Counsel | 0 | N/A |
| Hui Zhou | Chief R&D Officer for Oncology | 0 | N/A |
| Min Liu | Chief Commercial Officer | 0 | 1973 |
| Fei You | Chief Financial Officer | 0 | 1979 |
| Zhengwei Song | Director of IR & Financial Strategy | 0 | N/A |
| Kaisong Zhou | Chief Operating Officer | 0 | N/A |
| Raj Dhodda | Senior Vice President | 0 | N/A |
| Samuel Suhua Zhang | Global Chief Business Officer | 0 | 1968 |
| Blake Salisbury | Senior Vice President | 0 | N/A |
Description
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
